U.S. Building Stock News

QuidelOrtho recently announced a long-term supply agreement with Lifotronic Technology to broaden its immunoassay analyzer platforms and add over 70 assays, including more than 25 not currently offered on its VITROS system, across select markets outside the United States. This collaboration could materially reshape QuidelOrtho’s international diagnostics offering by helping it compete for full‑menu tenders and better serve both small and high‑throughput laboratories. Next, we’ll examine how...

Soleno Therapeutics (SLNO) just closed out FY 2025 with fourth quarter revenue of US$91.7 million and basic EPS of US$0.81, alongside net income of US$42.9 million. This capped a trailing 12 month line that shows revenue of US$190.4 million and basic EPS of US$0.40. The company reported revenue of US$66.0 million in Q3 and US$32.7 million in Q2, while EPS moved from US$0.49 in Q3 and a small loss in Q2. Together, these figures describe a story where higher sales and a cleaner income line are...

Ducommun (DCO) has wrapped up FY 2025 with fourth quarter revenue of US$215.8 million and basic EPS of US$0.50, alongside net income of US$7.4 million. The trailing twelve month figures show revenue of US$824.7 million and a net loss of US$33.9 million tied to basic EPS of US$2.27. Over recent quarters, revenue has moved from US$197.3 million in Q4 2024 to US$215.8 million in Q4 2025, with quarterly basic EPS ranging from a loss of US$4.30 in Q3 2025 to a profit of US$0.50 in Q4 2025. For...

Shake Shack (SHAK) has wrapped up FY 2025 with fourth quarter revenue of US$400.5 million and basic EPS of US$0.29, alongside trailing 12 month revenue of US$1.4 billion and EPS of US$1.14 that sit against very large reported earnings growth of 341.7% over the past year. The company has seen trailing 12 month revenue move from US$1.25 billion at the end of Q4 2024 to US$1.45 billion by Q4 2025, while trailing EPS stepped up from US$0.26 to US$1.14 and net profit margin shifted from 0.8% to...

In February 2026, Marcus & Millichap, Inc. reported fourth-quarter 2025 revenue of US$243.95 million and net income of US$13.31 million, alongside full-year 2025 revenue of US$755.16 million and a net loss of US$1.91 million, while also disclosing that it completed a share repurchase program totaling 3,146,936 shares for US$98.00 million. These results show improved quarterly profitability and a smaller full-year loss compared with the prior year, while the completed buyback reduced the...

Are you wondering if Global Industrial still offers good value after its recent run, or if the current price already reflects the key positives for the business? The stock last closed at US$33.26, with returns of 4.3% over 7 days, 9.9% over 30 days, 13.1% year to date, 48.4% over 1 year, 32.6% over 3 years and 10.4% over 5 years. This naturally raises questions about what is now priced in. Recent coverage has focused on Global Industrial's role as a distributor of industrial and business...

Axsome Therapeutics (NasdaqGM: AXSM) has started the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness. The trial focuses on a group of MDD patients who experience excessive daytime sleepiness, for which no approved treatments are currently available. This study expands Axsome's clinical program into an area of unmet medical need. Axsome Therapeutics, listed on the NasdaqGM under the ticker AXSM, develops therapies for central nervous...

SPX Technologies is pursuing an acquisition-led expansion and investing heavily in capacity, including in data center infrastructure. The company recently reported record earnings that align with this repositioning of its business mix. At the same time, insider selling and shifts in institutional ownership are reshaping who holds NYSE:SPXC shares. For investors, this mix of corporate activity and ownership changes makes NYSE:SPXC a stock to watch. The shares recently closed at $231.59, with...

Papa John's International FY 2025 Earnings Snapshot Papa John's International (PZZA) closed out FY 2025 with Q4 revenue of US$498.2 million and basic EPS of US$0.24, while trailing twelve month revenue came in at about US$2.1 billion with EPS of US$0.93. The company has seen quarterly revenue move from US$530.8 million in Q4 2024 to US$498.2 million in Q4 2025, with basic EPS shifting from US$0.45 to US$0.24 over the same period, and trailing net income excluding extra items sitting at...

Metropolitan Bank Holding (MCB) has completed and filed follow-on equity offerings totaling roughly US$353.5 million, issuing 2,100,000 common shares at US$85, a move that directly affects existing and prospective shareholders. See our latest analysis for Metropolitan Bank Holding. The follow on offerings come after a strong 1 year total shareholder return of 41.92% and a 3 year total shareholder return of 56.43%. However, recent momentum has cooled, with a 7 day share price return showing an...

If you are wondering whether Natera's current share price reflects its real value, you are not alone. This article will help you frame that question clearly. Natera's share price last closed at US$216.10, with a 7 day return of 0.1% decline, a 30 day return of 10.1% decline, a year to date return of 5.6% decline, and a 1 year return of 38.0%, alongside a very large 3 year return and a 111.6% return over 5 years. Recent headlines around Natera have kept the stock on many investors'...

Magnite (MGNI) closed out FY 2025 with Q4 revenue of US$205.4 million and basic EPS of US$0.86, capped by trailing 12 month EPS of US$1.01 that sits on trailing 12 month revenue of US$714.0 million. Over the past six quarters in this dataset, revenue has moved from US$162.0 million in Q3 2024 to US$205.4 million in Q4 2025, while quarterly EPS shifted from US$0.04 to US$0.86, creating a backdrop where margins have become a central focus for investors assessing the latest print. See our full...

In February 2026, Watsco, Inc. reported that its fourth-quarter 2025 sales fell to US$1,578.76 million and net income to US$71.75 million, and also approved a 10% increase in its annual dividend to US$13.20 per share for both Common and Class B shares. The combination of softer recent earnings and a higher dividend, underpinned by management’s emphasis on improved gross margins and a debt-free balance sheet, highlights how Watsco is prioritizing shareholder returns while contending with...

If you are looking at Credicorp and wondering whether the current share price still reflects solid value, you are not alone. This article will walk through what the numbers actually say. The stock last closed at US$355.48, with returns of 1.7% over 7 days, a marginal 0.2% decline over 30 days, 24.1% year to date, 106.7% over 1 year and 183.7% over 5 years. This naturally raises questions about how much future upside or risk is already built in. Recent news coverage has focused on Credicorp's...

Rhythm Pharmaceuticals (RYTM) has wrapped up FY 2025 with Q4 revenue of US$57.3 million and a basic EPS loss of US$0.73, while trailing 12 month figures show total revenue of US$189.8 million and a basic EPS loss of US$3.11. Over recent quarters, the company has seen revenue move from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, with basic EPS losses ranging between US$0.72 and US$0.82 per quarter. This sets up a story where revenue is building but margins remain under...

In February 2026, Jackson Financial Inc. reported fourth-quarter 2025 revenue of US$1,988 million but swung to a net loss of US$204 million, while also increasing its common dividend, declaring a preferred dividend, and completing a large share repurchase program that retired just over 40% of its shares since 2021. Despite record retail annuity sales and continued capital returns, the sharp drop in yearly net income to US$27 million and a move from earnings per share to a loss per share have...

Ultragenyx Pharmaceutical (NasdaqGS:RARE) announced that the US FDA has accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia. The FDA has granted Priority Review to the application, signaling an expedited assessment timeline. If approved, DTX401 could become the first pharmacologic treatment option for people living with Glycogen Storage Disease Type Ia. For Ultragenyx, with a current share price of $23.04, this regulatory milestone...

If you are looking at OceanFirst Financial and wondering whether its current share price lines up with its underlying worth, you are asking the exact question this article is built to tackle. The stock last closed at US$19.04, with returns of 3.8% over the past 30 days, 6.7% year to date, and 12.8% over the past year. The 3 year and 5 year returns sit at a 5.6% decline and a 5.0% gain respectively. These share price moves sit against a backdrop of ongoing sector wide attention on US regional...

MarketAxess Holdings (NasdaqGS:MKTX) has appointed William Quan as Chief Technology Officer to lead its AI and technology modernization efforts. The company has also announced an integration with DirectBooks that is designed to streamline primary market workflows for its clients. MarketAxess runs an electronic trading platform focused on fixed income markets, connecting institutional investors and dealers in credit products. The arrival of William Quan as CTO brings a leader with experience...

Several class action lawsuits have been filed against NuScale Power (NYSE:SMR) alleging misrepresentations about key commercialization partner ENTRA1 Energy. Plaintiffs claim NuScale understated the risks tied to ENTRA1, as fresh details emerge about substantial payments and project delays. At the same time, NuScale received approval for a small modular reactor project in Romania and major shareholder Fluor announced plans to exit its position. NuScale Power, trading at $13.33, is facing a...

Pennant Group’s FY 2025 Earnings Set Up the Next Phase of the Story The Pennant Group (PNTG) closed FY 2025 with fourth quarter revenue of US$289.3 million and basic EPS of US$0.25, capping a trailing twelve month period where revenue reached US$947.7 million and EPS came in at US$0.86. Over the past six reported quarters, the company has seen revenue move from US$188.9 million in Q4 2024 to US$289.3 million in Q4 2025, while quarterly EPS ranged between US$0.17 and US$0.25. This leaves...

If you are looking at Benchmark Electronics and wondering whether the current share price reflects its true worth, this article will walk through the key pieces you need to weigh that question up. The stock most recently closed at US$59.18, with returns of 3.2% over 7 days, 20.8% over 30 days, 34.8% year to date, 52.0% over 1 year and 163.2% over 3 years, so valuation now sits front and center for many investors. Recent coverage has focused on Benchmark Electronics as an established...

Pebblebrook Hotel Trust (PEB) has wrapped up FY 2025 with Q4 revenue of US$349.0 million, a basic EPS loss of US$0.23, and trailing twelve month revenue of about US$1.5 billion alongside a full year basic EPS loss of US$0.90. This gives investors a clear view of where the top line stands in relation to still negative earnings. The company has reported quarterly revenue moving from US$404.5 million in Q3 2024 to US$349.0 million in Q4 2025, while quarterly basic EPS has ranged from a loss of...

If you are wondering whether Atlanta Braves Holdings is fairly priced or trading at a premium, you are in the right place to unpack what the current share price might be telling you about value. The stock last closed at US$43.98, with reported returns of 2.5% over 7 days, 10.9% over 30 days, 10.3% year to date, 11.4% over 1 year and 50.1% over 5 years. These figures often prompt investors to reassess both upside potential and risk. Recent coverage around Atlanta Braves Holdings has focused...